Optimal concentration of bone morphogenetic protein 2 used to inhibit adipogenic differentiation of bone marrow mesenchymal stem cells

doi:10.3969/j.issn.2095-4344.2016.45.005

Abstract

Abstract:

BACKGROUND: Bone morphogenetic protein 2 cannot only promote osteogenesis, but also at different concentration ranges regulate the differentiation of bone marrow mesenchymal stem cells into adipocytes. Therefore, it is very important for the prevention and treatment of osteoporosis, if the range of concentrations of bone morphogenetic protein 2 can be found to regulate the differentiation of bone marrow mesenchymal stem cells into adipocytes, after the induction of bone marrow mesenchymal stem cells.
OBJECTIVE: To determine the optimal concentration of bone morphogenetic protein 2 to inhibit the differentiation of bone marrow mesenchymal stem cells into adipocytes.
METHODS: Bone marrow samples were obtained from the femur and tibia of rats. Primary cultured bone marrow mesenchymal stem cells were obtained by adherent culture method in vitro. Flow cytometry was used to identify the surface antigens of passage 2 bone marrow mesenchymal stem cells. Cells at passages 2 and 3 were taken and cultured in adipogenic induction medium for 3 days followed by the addition of 0.5, 5, 50, 100, 200 μg/L bone morphogenetic protein 2, or culture medium of bone marrow mesenchymal stem cells (control group), respectively.
RESULTS AND CONCLUSION: Bone marrow mesenchymal stem cells cultured were identified by the flow cytometry. Oil red O staining results showed that the increasing number of lipid droplets was shown in bone marrow mesenchymal stem cells induced by bone morphogenetic protein 2 under the increasing concentration of 0.5 to 50 μg/L; while the number of lipid droplets in bone marrow mesenchymal stem cells decreased after 17 days of induction with bone morphogenetic protein 2 under the concentration of 100 to 200 μg/L. These findings indicate that 100 μg/L bone morphogenetic protein 2 can inhibit adipogenic differentiation of bone marrow mesenchymal stem cell, so as to reduce the formation of adipocytes in rats. Therefore, 100 μg/L bone morphogenetic protein 2 is better to inhibit adipogenic differentiation of bone marrow mesenchymal stem cells.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Bone Morphogenetic Proteins, Adipogenesis, Tissue Engineering

CLC Number:

R394.2

Chen Ming, Zhang Tao, Liu Jun, Li Zhi-yun, Min Yan. Optimal concentration of bone morphogenetic protein 2 used to inhibit adipogenic differentiation of bone marrow mesenchymal stem cells[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(45): 6720-6725.

Figures/Tables 1

References

[1] López García-Franco A. Osteoporosis: How, when and how far. Aten Primaria. 2016;48(4):215-216.
[2] 王思成,杨雪骅,苏佳灿,等.抗骨质疏松药物临床应用的进展[J].中国组织工程研究与临床康复,2009,13(46): 9163-9166.
[3] Farahmand P, Spiegel R, Ringe JD. Male osteoporosis. Z Rheumatol. 2016;75(5):459-465.
[4] Kaur U, Chakrabarti SS, Gambhir IS. Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern. Curr Drug Saf. 2016;11(3):267-269.
[5] 刘异香.糖尿病骨质疏松的健康干预[J].中国实用医药, 2009,4(14):50-51.
[6] 陈明,喻恒锋,韩智敏,等.体位复位?围手术期鲑鱼降钙素及延期经皮椎体后凸成形术治疗骨质疏松性腰椎爆裂骨折[J].中国骨质疏松杂志,2013,19(10):1059-1068.
[7] 党莉.综合治疗骨质疏松椎体压缩性骨折腰背痛的疗效观察和护理[J].护士进修杂志,2011,26(7):664-665.
[8] 李鹏,龙洁,汤炜,等.bFGF和BMP-2联合应用对体外培养兔骨髓间充质干细胞增殖与骨向分化的影响[J].现代生物医学进展,2008,8(6):1011-1015.
[9] Crisan M, Solaimani Kartalaei P, Neagu A, et al. BMP and Hedgehog Regulate Distinct AGM Hematopoietic Stem Cells Ex Vivo. Stem Cell Reports. 2016;6(3): 383-395.
[10] 邓云贞,李珏丹,魏虹,等.BMP-2促进人炎症牙髓干细胞骨向诱导分化的体外研究[J].口腔生物医学,2015,6(2): 71-77.
[11] 章军辉,陈永强,汤亭亭,等.透明质酸复合BMP-2转染骨髓间充质干细胞修复兔桡骨干骨缺损[J].中华骨科杂志, 2005,25(10):37-41.
[12] 孙欣,曾荣,郭伟韬,等.BMP-2和p38MAPK在小鼠骨髓间充质干细胞向成骨细胞分化中的作用[J].广东医学院学报,2012,30(1):1-4.
[13] 周诺,麦华明,梁飞新,等.BMP-2?bFGF在牵引成骨中的表达及意义[J].口腔医学研究,2004,20(5):465-468.
[14] Zhang Z, Yang M, Wang Y, et al. Autophagy regulates the apoptosis of bone marrow-derived mesenchymal stem cells under hypoxic condition via AMP-activated protein kinase/mammalian target of rapamycin pathway. Cell Biol Int. 2016;40(6):671-685.
[15] 苗忠澄,高航.BMP-2预诱导骨髓间充质干细胞移植治疗大鼠再灌注后心肌梗死的实验研究[J].解放军医学杂志, 2014,39(8):601-608.
[16] Bandara N, Gurusinghe S, Chen H, et al. Minicircle DNA-mediated endothelial nitric oxide synthase gene transfer enhances angiogenic responses of bone marrow-derived mesenchymal stem cells. Stem Cell Res Ther. 2016;7:48.
[17] 陆斌,汤亭亭,岳冰,等.BMP-2基因转染的自体骨髓间充质干细胞修复羊股骨头坏死的生物力学研究[J].医用生物力学, 2005,20(2):71-75.
[18] 张雁儒,马辉,张辉,等. BMP-2转染BMSCs修复兔股骨头坏死模型的实验研究[J].中国临床解剖学杂志,2013, 31(4):447-452.
[19] Wang M, Zhang X, Xiong XI, et al. Bone Marrow Mesenchymal Stem Cells Reverse Liver Damage in a Carbon Tetrachloride-induced Mouse Model of Chronic Liver Injury. In Vivo. 2016;30(3):187-193.
[20] Nakano M, Nagaishi K, Konari N, et al. Bone marrow-derived mesenchymal stem cells improve diabetes-induced cognitive impairment by exosome transfer into damaged neurons and astrocytes. Sci Rep. 2016;6:24805.
[21] Zhang LT, Fang XQ, Chen QF, et al. Bone marrow-derived mesenchymal stem cells inhibit the proliferation of hepatic stellate cells by inhibiting the transforming growth factor β pathway. Mol Med Rep. 2015;12(5):7227-7232.
[22] Zhou J, Jiang L, Long X, et al. Bone-marrow-derived mesenchymal stem cells inhibit gastric aspiration lung injury and inflammation in rats. J Cell Mol Med. 2016; 20(9):1706-1717. [23] Beaudoin C, Jean S, Bessette L, et al. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int. 2016;27(9):2835-2844.
[24] Zheng S, Yang J, Tang Y, et al. Effect of bone marrow mesenchymal stem cells transplantation on the serum and liver HMGB1 expression in rats with acute liver failure. Int J Clin Exp Pathol. 2015;8(12):15985-15992.
[25] Lang H, Dai C. Effects of Bone Marrow Mesenchymal Stem Cells on Plasminogen Activator Inhibitor-1 and Renal Fibrosis in Rats with Diabetic Nephropathy. Arch Med Res. 2016;47(2):71-77.
[26] Lin GH, Lim G, Chan HL, et al. Recombinant human bone morphogenetic protein 2 outcomes for maxillary sinus floor augmentation: a systematic review and meta-analysis. Clin Oral Implants Res. 2016;27(11): 1349-1359.
[27] Kim JS, Cha JK, Lee JS, et al. Increased osteoinductivity and mineralization by minimal concentration of bone morphogenetic protein-2 loaded onto biphasic calcium phosphate in a rabbit sinus. J Periodontal Implant Sci. 2016;46(5):350-359.
[28] Goto F, Kakinuma S, Miyoshi M, et al. Bone morphogenetic protein-4 modulates proliferation and terminal differentiation of fetal hepatic stem/progenitor cells. Hepatol Res. 2016. in press.
[29] Allison SE, Chen Y, Petrovic N, et al. Activation of the pro-migratory bone morphogenetic protein receptor 1B gene in human MDA-MB-468 triple-negative breast cancer cells that over-express CYP2J2. Int J Biochem Cell Biol. 2016;80:173-178.
[30] Qian C, Zhu C, Yu W, et al. Bone morphogenetic protein 2 promotes osteogenesis of bone marrow stromal cells in type 2 diabetic rats via the Wnt signaling pathway. Int J Biochem Cell Biol. 2016;80: 143-153.
[31] Tellier LE, Miller T, McDevitt TC, et al. Hydrolysis and Sulfation Pattern Effects on Release of Bioactive Bone Morphogenetic Protein-2 from Heparin-Based Microparticles. J Mater Chem B Mater Biol Med. 2015; 3(40):8001-8009.
[32] Stiel N, Hissnauer TN, Rupprecht M, et al. Evaluation of complications associated with off-label use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in pediatric orthopaedics. J Mater Sci Mater Med. 2016;27(12):184.
[33] Merino D, Villar AV, García R, et al. BMP-7 attenuates left ventricular remodelling under pressure overload and facilitates reverse remodelling and functional recovery. Cardiovasc Res. 2016;110(3):331-345.
[34] Kim S, Choe S, Lee DK. BMP-9 enhances fibroblast growth factor 21 expression and suppresses obesity. Biochim Biophys Acta. 2016;1862(7):1237-1246.
[35] Villar AV, García R, Llano M, et al. BAMBI (BMP and activin membrane-bound inhibitor) protects the murine heart from pressure-overload biomechanical stress by restraining TGF-β signaling. Biochim Biophys Acta. 2013;1832(2):323-335.
[36] Wang S, Sun A, Li L, Zhao G, et al. Up-regulation of BMP-2 antagonizes TGF-β1/ROCK-enhanced cardiac fibrotic signalling through activation of Smurf1/Smad6 complex. J Cell Mol Med. 2012;16(10):2301-2310.
[37] Kaipel M, Schützenberger S, Hofmann AT, et al. Evaluation of fibrin-based gene-activated matrices for BMP2/7 plasmid codelivery in a rat nonunion model. Int Orthop. 2014;38(12):2607-2613.